기업
Genbody ‘Resurrection’.. Beginning export of Covid-19 rapid diagnostic kits
by Jongwon Jang
Genbody completed a contract of 4 million U.S. dollars in 10 countries. A total of 6.2 million contracts in progress. "Planning to apply for Urgent Use to the U.S. FDA"
Genbody, which attracted attention as Unicorn Company in the domestic in vitro diagnostic industry, has revived. Leveraging its know-how in mass production and export of virus diagnostic kits for Zika virus, the company has begun full-scale global export of novel coronavirus infectious disease (Covid-19) diagnostic kits.
Genbody received considerable attention during the 2016 Zika virus outbreak by developing and supplying the world's first rapid diagnostic kit and achieving sales of several hundred billion won in succession. However, the company has been in a slump due to a large drop in exports to Brazil, its main trading line, in 2019.
GenBody said on Monday, 30th, that they have obtained the Food and Drug Administration's export license for the Covid-19 Rapid Diagnostic Kit "GenBody COVID-19 IgM / IgG" and currently conducting export of 6.2 million kits with a total of 15 countries and LOI (Letter of Intent) in progress.
Countries in progress of contract are follows. In Asia, Malaysia, Vietnam, Indonesia, Bangladesh, Pakistan and other five countries; in South America, six countries including Panama, Brazil, Colombia, Venezuela, Chile, and Dominica; in Europe, Hungary, Ireland, and Turkey; in Africa, Nigeria and so on. First, the contracts have been completed and kits are being shipped, with exports reaching $ 3.96 million (approximately 4.84 billion won) in quantities that can test more than 1 million people in 10 countries.... <계속>
